The debate about the melanoma drug Keytruda is an important one, with some very familiar elements to it. At its most basic level, the question is should or should not Keytruda be funded by Pharmac so that affected patients can potentially benefit from it. So far, Keytruda has been registered by Medsafe, the medicines regulator, … Continue reading Dunne Speaks – An international approach to drug funding is needed